Daratumumab, the first antibody targeting CD38, has demonstrated sustained anti-tumor responses in clinical settings through mechanisms including antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity [41]. Here, CD38 is linked to neoplasm.